[The fifth day of the 2026 State Talks: Negotiation on the price of commercially insured innovative drugs begins. Many pharmaceutical companies enter the market with nuclear drugs, CAR-T new drugs and other blockbuster drugs] September 9th, at about 8 o'clock today, the fifth day of negotiation and bidding for the 2026 National Basic Medical Insurance Drug List and the price negotiation for the commercially insured innovative drugs officially started. The reporter learned on the spot that today is the last day of this year's State Talks, and intensive price negotiations for the commercially insured innovative drugs will be carried out. The negotiation and bidding for the basic medical insurance list were completed yesterday morning. Representatives from AstraZeneca, Sanofi, Keji Pharmaceutical subsidiary Kaixing Life, Yuanda, Hengrun Dasheng, Precision Biotech and other companies entered the negotiation venue one after another. This year, a total of 62 drug generic names were applied for in the commercial insurance innovative drug catalog price negotiation, and 58 passed the formal review, of which 57 were outside the catalog and 1 was within the catalog. Rare diseases, tumors, and neurological diseases were still the main applicants, accounting for about 70% in total. Two new CAR-T drugs, Hengrun Dasheng's Ranicchiolense Injection and Precision Biotech's Pulgeolense Injection, tried to "break through" for the first time. (Reporters Lu Afeng and Yu Miao)